Inveready Research
Investment Thesis
Founded in 2008, Inveready has grown from a Spanish venture capital pioneer into one of the most active multi-strategy alternative investment managers in Spain and, increasingly, Europe. The firm operates seven complementary investment platforms — Venture, Life Sciences, Private Equity, Credit, Infrastructure, Public Equity, and Client Solutions — under a single architecture built on financial creativity (tailor-made equity, debt, and hybrid structures), a multi-strategy model that lets it back companies at almost any stage of their lifecycle, and nearly two decades of accumulated know-how across market cycles. The firm frames its philosophy as "side by side": true alignment of interests between investors, management teams, and the companies it backs, rather than passive capital.
Platforms & Strategy
For F4-OS matching purposes the most relevant platform is Venture, a €306M AUM platform spanning 9 funds and 3 strategies: Venture Capital (pan-European hybrid equity and convertible debt for high-growth, technology-based companies in expansion phases and bridge rounds), Venture Debt (non-dilutive financing alongside or instead of equity rounds), and Industrial Growth Debt (CAPEX financing for innovative industrial companies). The separate Life Sciences platform runs dedicated biotech/pharma venture funds. Private Equity, Credit, Infrastructure, and Public Equity round out the firm's alternative-asset offering, giving Inveready reach into buyouts, direct lending, fixed income, infrastructure, and small/micro-cap public equities.
Stage Focus
The Venture platform's language ("expansion phases," "bridge financing between rounds") points to growth-stage and Series A/B technology companies rather than pre-seed formation, though its hybrid equity/debt toolkit lets it also support earlier and later rounds opportunistically. Life Sciences investments skew earlier, backing biotech/pharma platforms pre-clinical through commercialization.
Check Size
Third-party sources (Roundfunded, ConnectSafely investor directories) put typical Venture Finance check sizes around €1M–€5M, consistent with Venture Debt and convertible-note structures; this was not independently confirmed on Inveready's own site and should be treated as directional.
Lead Tendency
Unclear from public materials — Inveready plays both lead and participant roles depending on instrument (debt vs. equity) and platform; treated as unknown pending direct confirmation.
Recent Activity
Inveready has been actively deploying across platforms through 2026: a €5M Venture Debt financing for Mirai's bank risk-tech platform (Sept 2026), the launch of its first fund dedicated to search funds (Sept 2026), the creation of SERCOM as Spain's first integrated energy services group (Sept 2026), a €2.6M round backing Fresh People's AI-native leadership platform Booster (May 2026), a new private/asset-backed debt platform built with Terram Capital (Feb 2026), and the successful exit of Clerhp Estructuras with a return above 3x after supporting its growth on BME Growth (Jan 2026). The firm also published its 2025 ESG Report (May 2026).
Portfolio Highlights
Inveready's website lists roughly 190 active portfolio logos, and the firm states more than 275 total portfolio companies and 80+ exits since inception. Notable names span Digital Technology Venture Capital (Landbot, Multiverse Computing, Bit2me, Codeoscopic, Ironchip, IriusRisk, Zinklar), Life Sciences (Oryzon, Minoryx, VIVEbiotech, AB-Biotics, Palobiofarma), consumer/marketplace and proptech (Habyt, Lookiero, Stayforlong, Prontopiso), telecom (Másmóvil — a landmark exit that helped build the IBEX35 position referenced by CEO Josep Maria Echarri's board history — Parlem, Avatel, Ezentis, Voz Telecom), and edtech (Tekman Education, Ucademy, Netex Learning, Gamelearn).
Team
- Josep Maria Echarri — Managing Partner & CEO; founding partner, ex Vice Chairman of MásMóvil, oversees the €2.7Bn platform
- Aniol Brosa — General Partner leading the Digital Technology Venture Capital funds; former startup CEO/founder, ex-Accenture and Sabadell M&A
- Ernest Gassó — Investment Director for Venture Capital (Convertible Tech Notes) and Fund of Funds, ex-Accenture Strategy, CTO/co-founder of OptimalClinic
- Roger Font, Joan Matons — Venture Capital investment analysts
- Eduard Feliu — Managing Partner and CFO, ex-Deloitte/PwC auditor
- Carlos Conti — Managing Partner leading Private Equity, ex-UBS/BNP Paribas/JPMorgan
- Borja Fernández — General Partner leading Inveready Club Deal, 25 years in PE/M&A
- Ignacio Fonts — Non-Executive Chairman, ex-HP senior executive
Decision Process
Multiple General Partners and Managing Partners lead individual platforms and funds (partnership model), each platform's Executive-Committee-linked partner (e.g., Aniol Brosa for Digital Technology VC) driving deal decisions within their vertical.
Founder Preferences
Technical, high-growth technology founders in expansion phase, and biotech/life-sciences teams with a credible path to market — Inveready explicitly highlights backing Tryptyr, the first therapy originated at a Spanish research center to be approved in the US, with Inveready as lead initial investor.
Geographic Focus
Pan-European with a strong home base in Spain (offices in Barcelona, Madrid, and San Sebastián); the Industrial Growth strategy also reaches North America.